Effect of preoperative use of topical prednisolone acetate, ketorolac tromethamine, nepafenac and placebo, on the maintenance of intraoperative mydriasis during cataract surgery: A randomized trial

Indian Journal of Ophthalmology

Volumn 60, Issue 4, 2012, Pages 277-281

  Zanetti, Fernando Roberte ^a   Fulco, Enzo Augusto Medeiros ^a   Chaves, Fernando Rodrigo Pedreira ^a   Da Costa Pinto, Alexandre Paashaus ^a   Arieta, Carlos Eduardo Leite ^a   Lira, Rodrigo Pessoa Cavalcanti ^a  

^a UNIVERSITY OF CAMPINAS   (Brazil)

Author keywords

Cataract; inflammation; mydriasis; prevention and control; surgery

Indexed keywords

ANTIINFLAMMATORY AGENT; BENZENEACETAMIDE DERIVATIVE; DRUG DERIVATIVE; EYE DROPS; KETOROLAC TROMETAMOL; NEPAFENAC; PHENYLACETIC ACID DERIVATIVE; PREDNISOLONE; PREDNISOLONE ACETATE; PRODRUG; PROSTAGLANDIN SYNTHASE INHIBITOR;

AGED; ARTICLE; CATARACT EXTRACTION; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; FEMALE; FOLLOW UP; HUMAN; INTRAOPERATIVE PERIOD; MALE; METHODOLOGY; MYDRIASIS; POSTOPERATIVE COMPLICATION; PREOPERATIVE CARE; RANDOMIZED CONTROLLED TRIAL; RETROSPECTIVE STUDY; SINGLE BLIND PROCEDURE; TOPICAL DRUG ADMINISTRATION; TREATMENT OUTCOME;

ADMINISTRATION, TOPICAL; AGED; ANTI-INFLAMMATORY AGENTS; BENZENEACETAMIDES; CATARACT EXTRACTION; CYCLOOXYGENASE INHIBITORS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FOLLOW-UP STUDIES; HUMANS; INTRAOPERATIVE PERIOD; KETOROLAC TROMETHAMINE; MALE; MYDRIASIS; OPHTHALMIC SOLUTIONS; PHENYLACETATES; POSTOPERATIVE COMPLICATIONS; PREDNISOLONE; PREOPERATIVE CARE; PRODRUGS; RETROSPECTIVE STUDIES; SINGLE-BLIND METHOD; TREATMENT OUTCOME;

EID: 84864471862     PISSN: 03014738     EISSN: 19983689     Source Type: Journal    
DOI: 10.4103/0301-4738.98705     Document Type: Article

References (24)

1. Camras CB, Miranda OC. The putative role of prostaglandins in surgical miosis. Prog Clin Biol Res 1989;312:197-210.
2. Nichols J, Snyder RW. Topical nonsteroidal anti-inflammatory agents in ophthalmology. Curr Opin Ophthalmol 1998;9:40-4.
3. Schalnus R. Topical nonsteroidal anti-inflammatory therapy in ophthalmology. Ophthalmologica 2003;217:89-98.
4. Kim A, Stark WJ. Are topical NSAIDs needed for routine cataract surgery? Am J Ophthalmol 2008;146:483-5.
5. Duffin RM, Camras CB, Gardner SK, Pettit TH. Inhibitors of surgically induced miosis. Ophthalmology 1982;89:966-79.
6. Podos SM. Prostaglandins, nonsteroidal anti-inflammatory agents and eye disease. Trans Am Ophthalmol Soc 1976;74:637-60.
7. Kulkarni PS. Steroids in ocular therapy. In: Zimmerman TJ, editor. Textbook of Ocular Pharmacology. Philadelphia, PA: Lippincott-Raven; 1997. p. 63-7.
8. Shaikh MY, Mars JS, Heaven CJ. Prednisolone and flurbiprofen drops to maintain mydriasis during phacoemulsification cataract surgery. J Cataract Refract Surg 2003;29:2372-7.
9. Dubé P, Boisjoly HM, Bazin R, Chamberland G, Laughrea PA, Dubé I. Comparison of prednisolone acetate and indomethacin for maintaining mydriasis during cataract surgery. Can J Ophthalmol 1990;25:234-8.
10. Guzek JP, Holm M, Cotter JB, Cameron JA, Rademaker WJ, Wissinger DH, et al. Risk factors for intraoperative complications in 1000 extracapsular cataract cases. Ophthalmology 1987;94:461-6.
11. François J. Corticosteroid glaucoma. Ann Ophthalmol 1977;9: 1075-80.
12. Ocular Pharmacotherapeutics. In: Cantor LB, editor. American Academy of Ophthalmology -Fundamentals and Principles of Ophthalmology, 2007-2008 ed. San Francisco, CA: American Academy of Ophthalmology; 2007. p. 419-20.
13. Ke TL, Graff G, Spellman JM, Yanni JM. Nepafenac, a unique nonsteroidal prodrug with potential utility in the treatment of trauma-induced ocular inflammation: II. In vitro bioactivation and permeation of external ocular barriers. Inflammation 2000;24: 371-84.
14. Lindstrom R, Kim T. Ocular permeation and inhibition of retinal inflammation: An examination of data and expert opinion on the clinical utility of nepafenac. Curr Med Res Opin 2006;22:397-404.
15. Chylack LT, Leske MC, McCarthy D, Khu P, Kashiwagi T, Sperduto R. Lens opacities classification system II (LOCS II). Arch Ophthalmol 1989;107:991-7.
16. Cervantes-Coste G, Saínchez-Castro YG, Orozco-Carroll M, Mendoza-Schuster E, Velasco-Barona C. Inhibition of surgically induced miosis and prevention of postoperative macular edema with nepafenac. Clin Ophthalmol 2009;3:219-26.
17. Liou SW, Chen CC. Maintenance of mydriasis with one bolus of epinephrine injection during phacoemulsification. J Ocul Pharmacol Ther 2001;17:249-53.
18. Gimbel HV. The effect of treatment with topical nonsteroidal antiinflammatory drugs with and without intraoperative epinephrine on the maintenance of mydriasis during cataract surgery. Ophthalmology 1989;96:585-8.
19. Bhallil S, Andalloussi IB, El Abdouni O, Mahjoubi I, Tahri H. Is there a perioperative circulatory side effect of intracameral epinephrine in hypertensive patients undergoing phacoemulsification? Oman J Ophthalmol 2010;3:161-2.
20. Lundberg B, Behndig A. Intracameral mydriatics in phacoemulsification surgery obviate the need for epinephrine irrigation. Acta Ophthalmol Scand 2007;85:546-50.
21. Greenbaum S. Anesthesia for Eye Surgery. In: Tasman WS, Jaeger EP, editors. Duane's Clinical Ophthalmology. 2007 ed. Philadelphia: Lippincott Williams and Wilkins; 2007.
22. Duffin RM, Pettit TH, Straatsma BR. Maintenance of mydriasis with epinephrine during cataract surgery. Ophthalmic Surg 1983;14:41-5.
23. Slack JW, Edelhauser HF, Helenek MJ. A bisulfite-free intraocular epinephrine solution. Am J Ophthalmol 1990;110:77-82.
24. Stewart R, Grosserode R, Cheetham JK, Rosenthal A. Efficacy and safety profile of ketorolac 0.5% ophthalmic solution in the prevention of surgically induced miosis during cataract surgery. Clin Ther 1999;21:723-32.